期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 110, 期 37, 页码 14960-14965出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1309110110
关键词
estrogen signaling; mTORC1 signaling; ERK signaling; EMT
资金
- LAM Foundation
- Adler Foundation
- LAM Treatment Alliance
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health [CA046595, GM51405]
- National Heart Lung and Blood Institute [HL098216]
Lymphangioleiomyomatosis (LAM) is a destructive lung disease of women associated with the metastasis of tuberin-null cells with hyperactive mammalian target of rapamycin complex 1 (mTORC1) activity. Clinical trials with the mTORC1 inhibitor rapamycin have revealed partial efficacy but are not curative. Pregnancy appears to exacerbate LAM, suggesting that estrogen (E-2) may play a role in the unique features of LAM. Using a LAM patient-derived cell line (bearing biallelic Tuberin inactivation), we demonstrate that E-2 stimulates a robust and biphasic activation of ERK2 and transcription of the late response-gene Fra1 associated with epithelial-to-mesenchymal transition. In a carefully orchestrated collaboration, activated mTORC1/S6K1 signaling enhances the efficiency of Fra1 translation of Fra1 mRNA transcribed by the E-2-ERK2 pathway, through the phosphorylation of the S6K1-dependent eukaryotic translation initiation factor 4B. Our results indicate that targeting the E-2-ERK pathway in combination with the mTORC1 pathway may be an effective combination therapy for LAM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据